| BCBS Highmark West Virginia | Belantamab mafodotin (Blenrep) | 2026-07-01 |
| BCBS Highmark West Virginia | Treatment of Spinal Muscular Atrophy | 2026-07-01 |
| BCBS Highmark West Virginia | Intravitreal Injections | 2026-07-01 |
| UHC UMR Medical and Drug | Natalizumab (Tyruko® & Tysabri®) – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Natalizumab (Tyruko® & Tysabri®) – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Beds and Mattresses – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Carrier Testing Panels for Genetic Diseases – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Chelation Therapy – Commercial and Individual Exchange Medical Policy | 2026-07-01 |